Issue No, 798 of the Medical Technology Stock Letter includes a new recommendation (CBMG / Cellular Biomed) and the portfolio departure of PCYC (Pharmacyclics).
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.